2022年6月2日至3日，第12届HPV预防和控制会议在比利时安特卫普举行。本次技术会议重点讨论了几个主题。本报告总结了关于两个主题的讨论和经验教训：一剂HPV疫苗接种研究的更新情况和HPV疫苗接种后的体液免疫反应。哥斯达黎加（11年）和印度（10年）的长期追踪研究报告显示，在单剂HPV疫苗接种后，抗体水平保持稳定。在印度（接种后10年）和肯尼亚（接种后18个月）观察到的对HPV 16/18持续感染的高度疫苗有效性分别为95.4％（95％CI：85.0-99.9）和97.5％（81.7-99.7），这是在HPV感染率较高环境中的一个重要观察结果。在印度模拟了采用一剂HPV疫苗接种方案的潜在影响，并显示该方案的实施可以为实现世界卫生组织宫颈癌消除目标做出贡献。这些数据支持世界卫生组织SAGE关于女性9-20岁采用一剂HPV疫苗接种方案的建议。会议上还讨论了免疫桥接研究。大家一致认为，在审慎应用的情况下，它们可以支持和加速新的疫苗接种方案、年龄族群或疫苗配方的扩大使用。国际标准化的HPV免疫应答测量对于HPV疫苗学领域的进展非常重要。无论接种剂量多少，HPV疫苗接种后的体液免疫反应在24个月后趋于稳定，因此，必须在至少24个月的随访后进行数据分析以准确进行桥接研究。© 2023 由Elsevier Inc. 发表。

The 12th HPV Prevention and Control meeting was held on June 2-3, 2022, in Antwerp, Belgium. This technical meeting focused on several topics. This report summarises the discussions and lessons learned on two topics: an update on one-dose HPV vaccination studies and humoral immune responses upon HPV vaccination. Long-term follow-up studies from Costa Rica (eleven years) and India (ten years) report stable levels of antibodies after a single HPV vaccination. High vaccine effectiveness against incident persistent HPV 16/18 infection was seen in India (95.4%, 85.0-99.9) ten years postvaccination and in Kenya (97.5%, 81.7-99.7) eighteen months postvaccination, an important observation in a setting with a higher HPV prevalence. The potential impact of HPV vaccination using a one-dose schedule in India was modelled and showed that implementation of one-dose schedule can contribute towards achieving WHO Cervical Cancer elimination goals. These data support the WHO SAGE recommendations for adopting a one-dose schedule for females aged 9-20 years. Immunobridging studies were discussed during the meeting. General agreement was reached that when thoughtfully applied, they can support and accelerate the expanded use of HPV vaccine with new vaccine schedules, age cohorts, or vaccine formulations. Internationally standardised measurements of HPV immune responses important for the progress of HPV vaccinology field. Humoral immune responses upon HPV vaccination plateau at 24 months regardless of number of doses, therefore, data should be analysed after at least 24 months of follow-up to bridge studies accurately.© 2023 Published by Elsevier Inc.